Dr. Sharon joined CTEP in December 2011 as a Senior Investigator in the Investigational Drug Branch, where he works with academic investigators and industry collaborators to carry out the clinical development of promising new cancer therapies. His current portfolio includes immunotoxins, antibody-drug conjugates, immune-based monoclonal antibodies and other targeted agents. Dr. Sharon received his M.D. from Baylor College of Medicine in Houston, Texas in 2003. He completed his internal medicine residency at Emory University in 2006 and continued to work at Emory as a hospitalist and Clinical Instructor prior to his fellowship. Dr. Sharon completed his Hematology/Oncology Fellowship at the NIH in 2011, and during his fellowship, he obtained a Master of Public Health degree at the Harvard School of Public Health in 2009. His research at the NCI focused on mesothelioma and clinical investigations of targeted therapies, including immunotoxins. Other projects included clinical and translational projects aimed at decreasing immunogenenic responses in the host immune system. Dr. Sharon also has a particular interest in clinical effectiveness and comparative health systems. He previously worked as a guest at the Brookings Institution, helping plan and manage panels for the Brookings Institutionís inaugural Conference on Clinical Cancer Research, whose aim was to find consensus among stakeholders to find solutions to critical questions regarding the future of clinical cancer research. He has served as a reviewer for journals, such as Mabs, Value in Health, and Clinical Cancer Research.
National Cancer Institute
Executive Plaza North, Suite 7124
Rockville MD, 20852-7426